Literature DB >> 11012024

The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors.

E B Grant1, D Guiadeen, E Z Baum, B D Foleno, H Jin, D A Montenegro, E A Nelson, K Bush, D J Hlasta.   

Abstract

Beta-lactam antibiotics such as the cephalosporins and penicillins have diminished clinical effectiveness due to the hydrolytic activity of diverse beta-lactamases, especially those in molecular classes A and C. A structure activity relationship (SAR) study of a high-throughput screening lead resulted in the discovery of a potent and selective non-beta-lactam inhibitor of class C beta-lactamases.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11012024     DOI： 10.1016/s0960-894x(00)00444-3

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  21 in total

1.  Isatin derivatives with activity against apoptosis-resistant cancer cells.

Authors:  Nikolai M Evdokimov; Igor V Magedov; Dominic McBrayer; Alexander Kornienko
Journal:  Bioorg Med Chem Lett       Date:  2016-02-08       Impact factor: 2.823

2.  Testing the ability of rhodanine and 2, 4-thiazolidinedione to interact with the human pancreatic alpha-amylase: electron-density descriptors complement molecular docking, QM, and QM/MM dynamics calculations.

Authors:  Rajendran Niranjana Devi; Maria G Khrenova; Samuel Israel; Chellam Anzline; Andrey A Astakhov; Vladimir G Tsirelson
Journal:  J Mol Model       Date:  2017-08-05       Impact factor: 1.810

Review 3.  Current challenges in antimicrobial chemotherapy: focus on ß-lactamase inhibition.

Authors:  Carine Bebrone; Patricia Lassaux; Lionel Vercheval; Jean-Sébastien Sohier; Adrien Jehaes; Eric Sauvage; Moreno Galleni
Journal:  Drugs       Date:  2010-04-16       Impact factor: 9.546

4.  Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha.

Authors:  P H Carter; P A Scherle; J K Muckelbauer; M E Voss; R Q Liu; L A Thompson; A J Tebben; K A Solomon; Y C Lo; Z Li; P Strzemienski; G Yang; N Falahatpisheh; M Xu; Z Wu; N A Farrow; K Ramnarayan; J Wang; D Rideout; V Yalamoori; P Domaille; D J Underwood; J M Trzaskos; S M Friedman; R C Newton; C P Decicco; J A Muckelbauer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-09       Impact factor: 11.205

5.  An efficient microwave assisted synthesis of novel class of Rhodanine derivatives as potential HIV-1 and JSP-1 inhibitors.

Authors:  Sukanta Kamila; Haribabu Ankati; Edward R Biehl
Journal:  Tetrahedron Lett       Date:  2011-08-24       Impact factor: 2.415

6.  Three-component, one-flask synthesis of rhodanines (thiazolidinones).

Authors:  Alexander M Jacobine; Gary H Posner
Journal:  J Org Chem       Date:  2011-08-31       Impact factor: 4.354

7.  Rhodanine as a Potent Scaffold for the Development of Broad-Spectrum Metallo-β-lactamase Inhibitors.

Authors:  Yang Xiang; Cheng Chen; Wen-Ming Wang; Li-Wei Xu; Ke-Wu Yang; Peter Oelschlaeger; Yuan He
Journal:  ACS Med Chem Lett       Date:  2018-03-22       Impact factor: 4.345

8.  Rhodanine hydrolysis leads to potent thioenolate mediated metallo-β-lactamase inhibition.

Authors:  Jürgen Brem; Sander S van Berkel; WeiShen Aik; Anna M Rydzik; Matthew B Avison; Ilaria Pettinati; Klaus-Daniel Umland; Akane Kawamura; James Spencer; Timothy D W Claridge; Michael A McDonough; Christopher J Schofield
Journal:  Nat Chem       Date:  2014-11-17       Impact factor: 24.427

9.  Furanyl-rhodanines are unattractive drug candidates for development as inhibitors of bacterial RNA polymerase.

Authors:  Katherine R Mariner; Rachel Trowbridge; Anil K Agarwal; Keith Miller; Alex J O'Neill; Colin W G Fishwick; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

10.  Discovery and structure-activity relationship analysis of Staphylococcus aureus sortase A inhibitors.

Authors:  Nuttee Suree; Sung Wook Yi; William Thieu; Melanie Marohn; Robert Damoiseaux; Albert Chan; Michael E Jung; Robert T Clubb
Journal:  Bioorg Med Chem       Date:  2009-09-06       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.